Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Congenital Nephrogenic Diabetes Insipidus
NCT02460354Phase 1Terminated
- Sponsor
- Emory University
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in congenital nephrogenic diabetes insipidus (cNDI), sponsored by Emory University. Primary endpoint: Change in mean urine osmolality at 7 hours. Started Sep 2015; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
congenital nephrogenic diabetes insipidus (cNDI)
Beyond the preview
Go deeper on NCT02460354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460354.